Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 501 to 510 of 797

TitleReference numberPublishedLast updated
Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancerTA496
Naltrexone–bupropion for managing overweight and obesityTA494
Vismodegib for treating basal cell carcinomaTA489
Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxaneTA458
Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumoursTA488
Sarilumab for moderate to severe rheumatoid arthritisTA485
Aflibercept for treating choroidal neovascularisationTA486
Tofacitinib for moderate to severe rheumatoid arthritisTA480
Immunosuppressive therapy for kidney transplant in adultsTA481
Immunosuppressive therapy for kidney transplant in children and young peopleTA482

Results per page

  1. 10
  2. 25
  3. 50
  4. All